PHF19 before and post induction treatment possess favorable potency of reflecting treatment response to protease inhibitors, event-free survival, and overall survival in multiple myeloma patients

References

• Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma. JAMA. 2022;327(5):464–477. doi:10.1001/jama.2022.0003
   PubMed Web of Science ®Google Scholar
• Huang J, Chan SC, Lok V, et al. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol. 2022;9(9):e670–e677. doi:10.1016/S2352-3026(22)00165-X
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086–1107. doi:10.1002/ajh.26590
   PubMed Web of Science ®Google Scholar
• Goel U, Usmani S, Kumar S. Current approaches to management of newly diagnosed multiple myeloma. Am J Hematol. 2022;97(Suppl 1):S3–S25. doi:10.1002/ajh.26512
   PubMedGoogle Scholar
• Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(dagger). Ann Oncol. 2021;32(3):309–322. doi:10.1016/j.annonc.2020.11.014
   PubMed Web of Science ®Google Scholar
• Das S, Juliana N, Yazit NAA, et al. Multiple myeloma: challenges encountered and future options for better treatment. Int J Mol Sci. 2022;23(3):1649. doi:10.3390/ijms23031649
   PubMed Web of Science ®Google Scholar
• Liu W, Liu J, Song Y, et al. Mortality of lymphoma and myeloma in China, 2004-2017: an observational study. J Hematol Oncol. 2019;12(1):22. doi:10.1186/s13045-019-0706-9
   PubMedGoogle Scholar
• Gupta N, Sharma A, Sharma A. Emerging biomarkers in multiple myeloma: a review. Clin Chim Acta. 2020;503:45–53. doi:10.1016/j.cca.2019.12.026
   PubMed Web of Science ®Google Scholar
• Vizan P, Gutierrez A, Espejo I, et al. The polycomb-associated factor PHF19 controls hematopoietic stem cell state and differentiation. Sci Adv. 2020;6(32):eabb2745. doi:10.1126/sciadv.abb2745
   PubMed Web of Science ®Google Scholar
• Ghamlouch H, Boyle EM, Blaney P, et al. Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer. J Exp Clin Cancer Res. 2021;40(1):380. doi:10.1186/s13046-021-02185-1
   PubMed Web of Science ®Google Scholar
• Mason MJ, Schinke C, Eng CLP, et al. Multiple myeloma DREAM challenge reveals epigenetic regulator PHF19 as marker of aggressive disease. Leukemia. 2020;34(7):1866–1874. doi:10.1038/s41375-020-0742-z
   PubMed Web of Science ®Google Scholar
• Ren Z, Ahn JH, Liu H, et al. PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation. Blood. 2019;134(14):1176–1189. doi:10.1182/blood.2019000578
   PubMed Web of Science ®Google Scholar
• Schinke CD, Bird JT, Qu P, et al. PHF19 inhibition as a therapeutic target in multiple myeloma. Curr Res Transl Med. 2021;69(3):103290. doi:10.1016/j.retram.2021.103290
   PubMed Web of Science ®Google Scholar
• Li Y, Gong J, Zhang L. PHD finger protein 19 expression in multiple myeloma: association with clinical features, induction therapy outcome, disease progression, and survival. J Clin Lab Anal. 2021;35(9):e23910. doi:10.1002/jcla.23910
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Terpos E. Multiple myeloma. Ann Oncol. 2010;21( Suppl 7):vii143–vii150. doi:10.1093/annonc/mdq370
   PubMedGoogle Scholar
• Ludwig H, Miguel JS, Dimopoulos MA, et al. International Myeloma Working Group recommendations for global myeloma care. Leukemia. 2014;28(5):981–992. doi:10.1038/leu.2013.293
   PubMed Web of Science ®Google Scholar
• Greipp PR, Miguel S, Durie J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420. doi:10.1200/JCO.2005.04.242
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol. 2015;33(26):2863–2869. doi:10.1200/JCO.2015.61.2267
   PubMed Web of Science ®Google Scholar
• Maeda M, Takeshima H, Iida N, et al. Cancer cell niche factors secreted from cancer-associated fibroblast by loss of H3K27me3. Gut. 2020;69(2):243–251. doi:10.1136/gutjnl-2018-317645
   PubMed Web of Science ®Google Scholar
• Choudhury SR, Ashby C, Tytarenko R, et al. The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma. J Hematol Oncol. 2020;13(1):108. doi:10.1186/s13045-020-00933-y
   PubMed Web of Science ®Google Scholar
• Petruk S, Cai J, Sussman R, et al. Delayed accumulation of H3K27me3 on nascent DNA Is essential for recruitment of transcription factors at early stages of stem cell differentiation. Mol Cell. 2017;66(2):247–257 e245. doi:10.1016/j.molcel.2017.03.006
   PubMed Web of Science ®Google Scholar
• Boyle EM, Rosenthal A, Ghamlouch H, et al. Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups. Leukemia. 2022;36(2):591–595. doi:10.1038/s41375-021-01379-y
   PubMed Web of Science ®Google Scholar
• Yu T, Du C, Ma X, et al. Polycomb-like protein 3 induces proliferation and drug resistance in multiple myeloma and is regulated by miRNA-15a. Mol Cancer Res. 2020;18(7):1063–1073. doi:10.1158/1541-7786.MCR-19-0852
   PubMed Web of Science ®Google Scholar
• Garcia-Montolio M, Ballare C, Blanco E, et al. Polycomb factor PHF19 controls cell growth and differentiation toward erythroid pathway in chronic myeloid leukemia cells. Front Cell Dev Biol. 2021;9:655201. doi:10.3389/fcell.2021.655201
   PubMed Web of Science ®Google Scholar
• Keane NA, Glavey SV, Krawczyk J, et al. AKT as a therapeutic target in multiple myeloma. Expert Opin Ther Targets. 2014;18(8):897–915. doi:10.1517/14728222.2014.924507
   PubMed Web of Science ®Google Scholar
• Ghislin S, Deshayes F, Middendorp S, et al. PHF19 and Akt control the switch between proliferative and invasive states in melanoma. Cell Cycle. 2012;11(8):1634–1645. doi:10.4161/cc.20095
   PubMed Web of Science ®Google Scholar
• Xu B, Li J, Xu D, et al. PLK4 inhibitor plus bortezomib exhibits a synergistic effect on treating multiple myeloma via inactivating PI3K/AKT signaling. Ir J Med Sci. 2023;192(2):561–567. doi:10.1007/s11845-022-03007-9
   PubMed Web of Science ®Google Scholar
• Yang J, Qian J, Wezeman M, et al. Targeting β2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell. 2006;10(4):295–307. doi:10.1016/j.ccr.2006.08.025
   PubMed Web of Science ®Google Scholar
• Kin K, Kasahara T, Itoh Y, et al. beta2-Microglobulin production by highly purified human T and B lymphocytes in cell culture stimulated with various mitogens. Immunology. 1979;36(1):47–54.
   PubMed Web of Science ®Google Scholar
• Schardijn GH, van Eps S, W L. β2-microglobulin: its significance in the evaluation of renal function. Kidney Int. 1987;32(5):635–641. doi:10.1038/ki.1987.255
   PubMed Web of Science ®Google Scholar
• Schmidt-Hieber M, Gutierrez ML, Perez-Andres M, et al. Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells. Haematologica. 2013;98(2):279–287. doi:10.3324/haematol.2011.060632
   PubMed Web of Science ®Google Scholar
• Lee EF, Harris TJ, Tran S, et al. BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. Cell Death Dis. 2019;10(5):342. doi:10.1038/s41419-019-1568-3
   PubMedGoogle Scholar
• Luanpitpong S, Janan M, Yosudjai J, et al. Bcl-2 family members Bcl-xL and Bax cooperatively contribute to bortezomib resistance in mantle cell lymphoma. Int J Mol Sci. 2022;23(22):14474. doi:10.3390/ijms232214474
   PubMed Web of Science ®Google Scholar
• Pinto V, Bergantim R, Caires HR, et al. Multiple myeloma: available therapies and causes of drug resistance. Cancers (Basel). 2020;12(2):407. doi:10.3390/cancers12020407
   PubMed Web of Science ®Google Scholar
• Callander NS, Baljevic M, Adekola K, et al. Nccn guidelines(R) insights: multiple myeloma, version 3.2022. J Natl Compr Canc Netw. 2022;20(1):8–19. doi:10.6004/jnccn.2022.0002
   PubMed Web of Science ®Google Scholar
• Zhang T, Wang S, Lin T, et al. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma. Oncotarget. 2017;8(20):34001–34017. doi:10.18632/oncotarget.16987
   PubMedGoogle Scholar
• Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518–528. doi:10.1056/NEJMoa1714678
   PubMed Web of Science ®Google Scholar
• Facon T, Cook G, Usmani SZ, et al. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia. 2022;36(4):1066–1077. doi:10.1038/s41375-021-01488-8
   PubMed Web of Science ®Google Scholar
• Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(11):1582–1596. doi:10.1016/S1470-2045(21)00466-6
   PubMed Web of Science ®Google Scholar